New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
07:24 EDTRNA, NPSP, GEVA, CNAT, XOMA, RARE, NLNK, FOLD, ADXS, VRTX, PLX, ISIS, CYTKCanaccord to hold a conference
Orphan Drugs 1:1 Day will be held in New York on February 24.
News For ADXS;CNAT;CYTK;FOLD;GEVA;ISIS;NLNK;NPSP;PLX;RARE;RNA;VRTX;XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 29, 2015
07:47 EDTVRTXCerulean appoints Stuart A. Arbuckle to board of directors, effective June 26
Subscribe for More Information
05:51 EDTXOMAStocks with implied volatility movement; XOMA EXEL
Subscribe for More Information
June 26, 2015
09:41 EDTXOMAXOMA mentioned positively by Biotech Insider
06:05 EDTXOMAStocks with implied volatility above IV index mean; XOMA NBG
Subscribe for More Information
June 25, 2015
17:28 EDTNLNKNewLink Genetics files $250M mixed securities shelf
Subscribe for More Information
16:04 EDTFOLDAmicus says EMA validates Galafold marketing authorization application
Subscribe for More Information
07:34 EDTADXSAdvaxis provides milestones outlook for 2015 and 2016
The company anticipates the following milestones through the remainder of 2015 and into 2016 for ADXS-HPV: Commence enrollment in the Phase 3, registration quality trial, AIM2CERV; Complete enrollment in Stage 2 of the ongoing GOG-0265 Phase 2 trial of ADXS-HPV in persistent or recurrent cervical cancer being conducted by the Gynecologic Oncology Group, anticipating up to 38 patients enrolled by June 30, 2016 with Final Stage 1 safety and efficacy data to be presented at an upcoming major medical meeting in 2015. Final study data to be available in the first half of 2017; Enroll the first patient this summer in a collaborative Phase 1/2 study of ADXS-HPV in combination with AstraZeneca/MedImmune's MEDI4736 in cervical cancer and HPV-associated head and neck cancer in second half of 2015 with data available in the first half of 2016; Complete enrollment in Part A of our Phase 1 study evaluating higher doses of ADXS-HPV immunotherapy and repeat cycles of treatment with data available from Part A in 2016. Complete enrollment of the Mount Sinai investigator-sponsored Phase 1/2 study of ADXS-HPV in patients with HPV-associated head and neck cancer. Data to be available in the first half of 2016; Commence enrollment in a Phase 2 study in patients with HPV-associated metastatic anal cancer by year's end with data available in the second half of 2016; Commence enrollment in the second half of 2015 on the Phase 1/2 combination study with Incyte Corporation's IDO-1 inhibitor. Expects to complete enrollment in Part A in the first half of 2016 in the Phase 1/2 study of ADXS-PSA as a monotherapy or in combination with Merck's anti-PD-1 therapy, Keytruda, in metastatic, castration-resistant prostate cancer. Data to be available in second half of 2016. Expects to enroll the first patient in a Phase 1 first-in-human trial of ADXS-HER2 in metastatic HER2 expressing solid tumors in the second half of 2015 with data to be available in the second half of 2016; Initiate a clinical study of ADXS-HER2 in pediatric osteosarcoma in partnership with the Children's Oncology Group in 2016; Secure conditional license for ADXS-HER2 for the treatment of canine osteosarcoma from the U.S. Department of Agriculture in 2016.
07:09 EDTCNATConatus announces initial baseline data from Phase 2b POLT-HCV-SVR trial
Conatus announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the company's Phase 2b clinical trial of its lead drug candidate, emricasan, in post-orthotopic liver transplant, or POLT, recipients. These patients have reestablished liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus, or HCV, infection and have successfully achieved a sustained viral response, or SVR, following HCV antiviral therapy, or POLT-HCV-SVR. Among the first 16 patients enrolled, more than 85% achieved SVRs using recently approved oral HCV antiviral treatments. The excitement generated by these new treatments altered enrollment patterns during the early stage of the POLT-HCV-SVR trial, and their rapid market penetration is now expanding the trial-eligible population. The double-blind, placebo-controlled trial was initiated in May 2014 in patients with Ishak Fibrosis Scores of 2 to 4. Consistent with the company's initial registration focus on the development of a treatment for cirrhosis, the trial was expanded in early 2015 to include patients with Ishak 5 and is currently expanding to Ishak 6. Patients are being randomized 2:1 to receive either 25 mg of emricasan or placebo orally twice daily for 24 months and will be followed for another month post-treatment. The primary endpoint in this exploratory proof-of-concept trial is the change in the Ishak Fibrosis Score compared with placebo. The trial will also evaluate histological markers of inflammation, key serum biomarkers, and the safety and tolerability of emricasan in the target patient population. Enrollment of approximately 60 total planned patients is on track for release of final top-line results in the first half of 2018.
05:57 EDTXOMAStocks with implied volatility above IV index mean; XOMA YELP
Subscribe for More Information
June 24, 2015
11:19 EDTADXSAdvaxis management to meet with Jefferies
Subscribe for More Information
05:57 EDTXOMAStocks with implied volatility above IV index mean; XOMA THC
Stocks with implied volatility above IV index mean; XOMA (XOMA) 169, Tenet (THC) 51 according to iVolatility.
June 23, 2015
18:04 EDTISISIsis Pharma granted FDA orphan status for treatment of familial chylomicronemia
Subscribe for More Information
08:58 EDTISISIsis Pharmaceuticals shares not reflecting SMA data, says Needham
Subscribe for More Information
06:32 EDTGEVAAlexion completes acquisition of Synageva
Subscribe for More Information
05:57 EDTXOMAStocks with implied volatility above IV index mean; XOMA YELP
Subscribe for More Information
June 22, 2015
14:08 EDTXOMAXOMA calls active as shares rally
Subscribe for More Information
09:25 EDTRAREUltragenyx appoints Jayson Dallas, M.D., as Chief Commercial Officer
Subscribe for More Information
07:01 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx in Phase 2 study
Subscribe for More Information
06:33 EDTGEVAAlexion accepts shares of Synageva tendered into exchange offer
Subscribe for More Information
June 19, 2015
10:42 EDTADXSAdvaxis to host business news update conference call
Conference call to be held on June 25 at 8:30 am. Webcast Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use